Multimodal therapies have aroused great interest in tumor therapy due to their highly
effective antitumor effect. However, immune clearance limits the practical application of …

Colorectal cancer (CRC) is the third most revalent type of cancer in the world and the
second most common cause of cancer death (about 1 million per year). Historically, natural …

This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus
durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable …

Background The proteome is a major source of therapeutic targets. We conducted a
proteome-wide Mendelian randomization (MR) study to identify candidate protein markers …

Background Previous investigations of transcriptomic signatures of cancer patient survival
and post-therapy relapse have focused on tumor tissue. In contrast, here we show that in …

The revolution of precision medicine has produced unprecedented seismic shifts in the
treatment paradigm of advanced cancers. Among the major killers, colorectal cancer (CRC) …

Abstract Purpose: Circulating tumor DNA (ctDNA) has the potential to guide therapy
selection and monitor treatment response in patients with metastatic cancer. However …

The incidence of metabolism-related diseases like obesity and type 2 diabetes mellitus has
reached pandemic levels worldwide and increased gradually. Most of them are listed on the …

Over the last decade, there have been improvements in colorectal cancer (CRC) incidence
and survival. 1–5 These outcomes are attributed to multidisciplinary advances, including the …

Colorectal cancer (CRC) is one of the most common and fatal cancers worldwide, yet
therapeutic options for CRC often exhibit strong side effects which cause patients' well-being …